ASH 2017 highlights: Cell therapy approaches in ALL

Stephan Grupp

Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, Philadelphia, PA, talks about some of the different cell therapy approaches spoken about at ASH 2017. 2017 has been an exciting year for ASH due to the FDA approval of some CAR-T products including, Novartis’ CTL019 or Kymriah, which is being used in children with ALL. Another of Dr Grupp’s highlights was the interesting data which presented about a humanized version of the CD19-targeted CAR in patients with ALL, which has shown some great results.
Recorded at the American Society of Hematology 2017 Annual Meeting, held in Atlanta, GA.

Share this video